FGFR1 agonists and methods of use

A method of treating diabetes in an individual, comprising administering to the individual an effective amount of an anti-Fibroblast Growth Factor Receptor 1 (FGFR1) antibody, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence GFTFTSNWIS (SEQ ID NO:

• 9), (b) HVR-H2 comprising an amino acid sequence selected from the group consisting of AEIDPYDGATDYADSVKG (SEQ ID NO:
• 14) and EIDPYDGATDYADSVKG (SEQ ID NO:15), (c) HVR-H3 comprising an amino acid sequence selected from the group consisting of TGTDVMDY (SEQ ID NO:
• 19) and GTDVMDY (SEQ ID NO:
• 20), (d) HVR-L1 comprising the amino acid sequence RASQDVSTAVA (SEQ ID NO:
• 21);
• (e) HVR-L2 comprising the amino acid sequence SASFLYS (SEQ ID NO:
• 22);
• and (f) HVR-L3 comprising the amino acid sequence QQSYTTPPT (SEQ ID NO:
• 23).